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also be treated. On the other hand, perfusing vessels in
nonpulsatile aneurysms are observed for signs of aneurysm
growth. If the etiology of the endoleak is unclear, we find
ourselves in a quandary and undergo a detailed evaluation
of the potential collateral vessels. We may rely on the
expected decrease in aneurysm size to help delineate a
treatment course, or we may perhaps even treat the
endoleak merely to definitively establish the diagnosis. A
nonpalpable aneurysm is treated in a more aggressive fash-
ion than a palpable, nonpulsatile aneurysm. In this situa-
tion, we believe the risks of observation are largely
unknown, and without knowledge of the extent of the
physical forces on the aneurysm wall, the risks of observa-
tion may outweigh the risks of treatment. Quantifications
of these forces are under investigation but have not yet
entered into the clinical arena.6,7 Although some may crit-
icize this protocol as being overly aggressive, we believe
that the overall validity of endovascular repair will depend
on long-term efficacy, which is, at this point, undefined.
Differences between this decision tree and published
regimens include a means to determine the need for
aggressiveness in patients with either undefinable endoleaks
or those caused by perfusing vessels. Fundamental to this
algorithm is that the follow-up physical examinations be
coupled with radiographic evaluation and that a clinician
evaluate the patient both before and after surgery, paying
careful attention to the findings of the physical examina-
tion. Furthermore, this information should be noted in fol-
low-up examination. Because endovascular grafting tech-
niques have lead us down a highly technical path, we are,
in a sense, recommending a step backward to reemphasize
the role and need for the clinical examination.
Roy Greenberg, MD
Department of Vascular Surgery
Cleveland Clinic Foundation
Richard Green, MD
Division of Vascular Surgery
University of Rochester
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Regarding “In situ replacement of infected aortic
grafts with rifampicin-bonded prostheses: the
Leicester experience (1992 to 1998)” 
To the Editors:
In the article by Hayes and colleagues (J Vasc Surg
1999:30:92-8), the authors referred to one of our publica-
tions and erroneously stated that we have suggested that a
polytetrafluoroethylene graft may be used for in situ replace-
ment of infected aortic prostheses.1 The paper that the
authors refer to was addressing whether infected prosthetic
grafts could be preserved successfully, but never suggested
that a new prosthetic graft be used to replace a previously
excised infected prosthetic graft. We have never suggested
this as a option to treat infected prosthetic grafts.2 We believe
that it is extremely important that readers of the article by
Hayes et al do not believe that we are in favor of placing a
new prosthetic graft into an infected field, although the role
of rifampicin-bonded prostheses may prove to be useful.
Keith D. Calligaro, MD
Pennsylvania Hospital
Philadelphia, Pa 
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Reply
We are pleased that Dr Calligaro notes that in situ
replacement with rifampicin-bonded grafts may have a role
to play in the management of graft infection. We accept that
Dr Calligaro and colleagues1 have not previously recom-
mended the replacement of infected prosthetic grafts with a
further prosthetic graft, rather their selective preservation in
extracavitary graft infections. For intracavitary infections,
the focus of our paper, the mainstays of treatment are graft
excision followed by either in situ replacement or extra-
anatomic bypass (EAB). We believe that in situ replacement
overcomes a number of the problems of EAB, namely,
stump blowout, poor flows, lower patency, and prolonged
procedure time. The use of antibiotic-bonded grafts may
